Expression of Stress-associated Endoplasmic Reticulum Protein 1 (SERP1) in Patients with Vitiligo | ||||
| Egyptian Journal of Medical Research | ||||
| Volume 6, Issue 3, July 2025, Page 36-47 PDF (498.62 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejmr.2022.153132.1256 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hala Ahmed Saad  1; Abd-El Aziz Ahmed El- Rifaie 1; Laila Ahmed Rashed 2; Mona Elsayed Ahmed Abdellatif1
| ||||
| 1Dermatology, Venereology and Andrology department, Faculty of Medicine, Beni-Suef University, Egypt | ||||
| 2Medical Biochemistry and Molecular Biology department, Faculty of Medicine, Cairo University, Egypt | ||||
| Abstract | ||||
| Vitiligo stands out as one of the most common pigmentary skin disorders. This condition is marked by the presence of localized depigmented macules or patches, which arise due to the loss of melanocytes. The expression of stress-associated endoplasmic reticulum protein 1 (SERP1), also known as ribosome-associated membrane protein 4 (RAMP4), increased in response to stress that led to the buildup of unfolded proteins during endoplasmic reticulum (ER) stress. The aim of this study is to determine the relationship between SERP1 and the causes of vitiligo through real-time qPCR analysis. SERP1 was detected in a cohort of 30 vitiligo patients and 30 healthy controls using real-time quantitative polymerase chain reaction (qPCR). The expression of SERP1 in tissue showed a significant increase in Vitiligo skin lesions when compared to healthy skin samples from controls. SERP1 plays a role in the development of vitiligo. | ||||
| Keywords | ||||
| Vitiligo; stress-associated endoplasmic reticulum protein 1; Endoplasmic reticulum stress | ||||
| References | ||||
|
1- Abdelmoneim T A, Aljarbou A N, Alfarouk K O (2018): The Prevalence of Vitiligo Variants in Association with Helicobacter pylori Infection. American Journal of Dermatology and Venereology; 7(1), 1-5.
2- Iannella G, Greco A, Didona D (2016): Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmunity Reviews;15(4), 335-343.
3- Picardo M, Dell'Anna ML, Ezzedine K (2015): Vitiligo. Nat Rev Dis Primers;1,150-200.
4- Rahman R and Hasija Y (2018): Exploring vitiligo susceptibility and management: a brief review. Biomedical Dermatology;2(1), 20-28.
5- Picardo M and Bastonini E (2015): A new view of vitiligo: looking at normal-appearing skin. Journal of Investigative Dermatology; 135(7), 1713-1714.
6- Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., & Papaioannou, A. (2019). Endoplasmic reticulum stress signalling–from basic mechanisms to clinical applications. The FEBS journal, 286(2), 241-278.
7- Xu W and Wang X (2019): Detection of melanocyte lineage‑specific genes in vitiligo lesions. Experimental and therapeutic medicine; 17(6), 4485-4491.
8- Ma, Q., Wu, X., Wu, J., Liang, Z., & Liu, T. (2017). SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis. International journal of oncology, 51(4), 1104-1114.
9- Tian J N, Yang C C, Chuang C K (2019): A Dengue Virus Type 2 (DENV-2) NS4B-Interacting Host Factor, SERP1, Reduces DENV-2 Production by Suppressing Viral RNA Replication. Viruses; 11(9), 787-785.
10- Ezzedine, K., Eleftheriadou, V., Whitton, M. & Geel, N. V. (2015).Vitiligo. Lancet 386, 74–84 .
11- Li, K., Shi, Q., Yang, L., Li, X., Liu, L., Wang, L., & Gao, T. W. (2012). The association of vitamin D receptor gene polymorphisms and serum 25‐hydroxyvitamin D levels with generalized vitiligo. British Journal of Dermatology, 167(4), 815-821.
12- Al Houssien, A. O., Al Houssien, R. O., Al Ajroush, W., & Al Kahtani, H. S. (2017). Chronic diseases among vitiligo patients: A case control study. Saudi medical journal, 38(4), 400-465.
13- Frisoli MI, Harris JE. (2017). Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol; 140: 654-662.
14- Wang, M., Law, M. E., Castellano, R. K., & Law, B. K. (2018).The unfolded protein response as a target for anticancer therapeutics. Critical reviews in oncology/hematology, 127, 66-79.
15- Chen, J. X., Shi, Q., Wang, X. W., Guo, S., Dai, W., Li, K., & Gao, T. W. (2014). Genetic polymorphisms in the methylenetetrahydrofolate reductase gene (MTHFR) and risk of vitiligo in Han Chinese populations: a genotype–phenotype correlation study. British Journal of Dermatology, 170(5), 1092-1099.
16- Vaccaro, M., Cicero, F., Mannucci, C., Calapai, G., Spatari, G., Barbuzza, O., & Gangemi, S. (2016). IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo. Archives of dermatological research, 308(7), 527-530.
17- Xu, M., Liu, Y., Liu, Y., Li, X., Chen, G., Dong, W., & Xiao, S. (2018). Genetic polymorphisms of GZMB and vitiligo: a genetic association study based on Chinese Han population. Scientific reports, 8(1), 1-5.
18- Ebrahim, A. A., Hamed, A. M., Ahmed, E. S., & Khudhair, A. S. (2018).Evaluation of serum interleukin-33 in nonsegmental vitiligo. Benha Medical Journal, 35(1), 54-70.
19- Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgil SG. 2012. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol; 37: 62–64.
20- Dash R, Mohapatra A, Manjunathswamy BS. (2015). Anti-thyroid peroxidase antibody in vitiligo: a prevalence study. J Thyroid Res;145-146.
21- Sorour, N. E., Alkady, O. H., El Fallah, A. A., Mansour, A. I., & Abdelwahab, W. W. (2020). Evaluation of S100B Serum levels in non-segmental vitiligo patients. Benha Journal of Applied Sciences, 5(1 part (2)), 1-7.
22- Saunders LR, Verdin E.(2007). Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-504.
| ||||
|
Statistics Article View: 75 PDF Download: 29 |
||||
